Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company, announced today that its customer Coherus BioSciences, Inc (“Coherus”) has launched its UDENYCA® on-body injector (OBI) utilizing the ...To the press release of LTS Lohmann Therapie-Systeme AG
Andernach (ots) - LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The purpose of the grant is to support the development of microneedle array patches (MAP) for ...To the press release of LTS Lohmann Therapie-Systeme AG
Andernach (ots) - LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The grant will support new formulation methods for mRNA, such as dissolvable microneedle array ...To the press release of LTS Lohmann Therapie-Systeme AG
Andernach (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) and Micro ...To the press release of LTS Lohmann Therapie-Systeme AG
Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”), a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (“TTS”), Oral Thin Films (“OTF”) ...To the press release of LTS Lohmann Therapie-Systeme AG
Andernach, Germany (ots) - LTS LOHMANN Therapie-Systeme AG (“LTS”) announces the closing of the acquisition of Tapemark Inc. (“Tapemark”) located in St. Paul, MN, USA. This acquisition combines Tapemark, a world-class CDMO specialized in ...To the press release of LTS Lohmann Therapie-Systeme AG
